Nicole Kallewaard | Associate Director, Microbial Sciences

Nicole Kallewaard, Associate Director, Microbial Sciences, AstraZeneca

Dr. Nicole Kallewaard leads the Targeted Therapeutics arm of AstraZeneca’s Microbial Sciences Department, which discovers and develops innovative medicines targeting the microbiome and specific bacterial and viral pathogens. Dr. Kallewaard has led cross-functional teams to progress antibody candidates from early discovery through clinical development and contributed to regulatory submissions of several antibody drugs targeting respiratory syncytia virus and influenza. She has several patents describing novel antiviral biologics and has been a leader in the development of in vivo expressed biologics platforms at AstraZeneca. Dr. Kallewaard earned a BS in Microbiology from Michigan State University, a PhD in Microbiology and Immunology from Vanderbilt University, and did her postdoctoral fellowship at the Children’s Hospital of Philadelphia.


Pre-congress Workshops, April 6 @ 10:00


The role of vaccines in preventing outbreaks, through natural causes or biothreatsIt only takes natural outbreaks and bioterrorism attacks like the Ebola and anthrax to highlight the danger and fragile balance we live in. To ensure global and international security, important decisions need to be made in stockpiling and prioritizing research efforts, however there is a lack of vaccine manufacturers producing these countermeasure treatments. Participate in this workshop to understand the rationale for developers to produce these lower commercial interest vaccines, and the challenges/opportunities associated in working with the government.
  • NIAID’s gap filling preclinical services for vaccine development
  • Expanding the utility of biodefense vaccines
  • Biodefense and Pandemic Preparedness:Two sides of the same coin?
  • Update on the broadly neutralizing influenza monoclonal antibody used for the DARPA-funded Pandemic Preparedness Platform (P3) initiative
  • A disruptive, transportable mRNA vaccine manufacturing platform that can rapidly combat multiple diseases
last published: 05/Mar/20 10:35 GMT

back to speakers

Sign Up for Event Updates